Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial

Pia von Blanckenburg, Franziska Schuricht, Ute-Susann Albert, Winfried Rief, Yvonne Nestoriuc, Pia von Blanckenburg, Franziska Schuricht, Ute-Susann Albert, Winfried Rief, Yvonne Nestoriuc

Abstract

Background: Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients' quality of life and cause non-adherence. The recently demonstrated effect of individual expectations on side-effect development (nocebo effect) suggests that psychological factors play a role in the prevention of side effects. The aim of this study is to evaluate cognitive-behavioral side-effect prevention training (SEPT) for breast cancer patients. This article describes the study protocol and applied research methods.

Methods/design: In a randomized controlled trial, 184 female breast cancer patients are assigned to receive either SEPT, standard medical care or a manualized supportive therapy at the start of adjuvant endocrine treatment. SEPT consists of three sessions of cognitive-behavioral training including psychoeducation to provide a realistic view of endocrine therapy, imagination-training to integrate positive aspects of medication into daily life, and side-effect management to enhance expectations about coping ability. Side effects three months after the start of endocrine therapy serve as primary outcomes. Secondary outcomes include quality of life, coping ability and patients' medication adherence. Patients' expectations (i.e., expectations about side effects, coping ability, treatment and illness) are analyzed as mediators.

Discussion: The optimization of expectations might be a potential pathway in health care to improve patients' quality of life during long-term medication intake. The results will provide implications for a possible integration of evidence-based prevention training into clinical practice.

Trial registration: ClinicalTrials.gov, (NCT01741883).

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Intervention schedule.

References

    1. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J. et al.American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784–3796. doi: 10.1200/JCO.2009.26.3756.
    1. Kreienberg R, Albert US, Follmann M, Kopp I, Kühn T, Wöckel A, Zemmler T. In: Leitlinienprogramm Onkologie. AWMF, Deutsche Krebsgesellschaft e.V. und Deutsche Krebshilfe e.V, editor. Zuckschwerdt: München; 2012. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms.
    1. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M. et al.Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–518. doi: 10.1200/JCO.2009.23.1274.
    1. Howell A, Cuzick J, Baum A, Buzdar A, Dowsett M, Forbes J, Hoctin-Boes G, Houghton J, Locker GY, Tobias S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62.
    1. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20:431–436.
    1. Neugut A, Hillyer G, Kushi L, Lamerato L, Leoce N, Nathanson S, Ambrosone C, Bovbjerg D, Mandelblatt J, Magai C. et al.Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the breast cancer quality of care study (BQUAL) Breast Cancer Res Treat. 2012;134:419–428. doi: 10.1007/s10549-012-2066-9.
    1. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–4128. doi: 10.1200/JCO.2009.25.9655.
    1. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–562. doi: 10.1200/JCO.2007.11.5451.
    1. Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L, Kwan M, Gomez S, Neugut A. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–537. doi: 10.1007/s10549-010-1132-4.
    1. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322–328.
    1. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273–284. doi: 10.1007/s10549-006-9260-6.
    1. Cella D, Fallowfield L. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107:167–180. doi: 10.1007/s10549-007-9548-1.
    1. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;4 CD003370.
    1. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622–627. doi: 10.1001/jama.287.5.622.
    1. Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med. 2006;166:155–160. doi: 10.1001/archinte.166.2.155.
    1. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ. et al.Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23:6931–6940. doi: 10.1200/JCO.2005.11.181.
    1. Colloca L, Miller FG. Role of expectations in health. Curr Opin Psychiatr. 2011;24:149. doi: 10.1097/YCO.0b013e328343803b.
    1. Rief W, Bingel U, Schedlowski M, Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther. 2011;90:722–726. doi: 10.1038/clpt.2011.204.
    1. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Predection of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res. 2010;62:791–799.
    1. Roscoe JA, Jean-Pierre P, Shelke AR, Kaufman ME, Bole C, Morrow GR. The role of patients’ response expectancies in side effect development and control. Curr Probl Cancer. 2006;30:40–98. doi: 10.1016/j.currproblcancer.2005.12.001.
    1. Colagiuri B, Zachariae R. Patient expectancy and post-chemotherapy nausea: a meta-analysis. Ann Behav Med. 2010;40:3–14. doi: 10.1007/s12160-010-9186-4.
    1. Sohl SJ, Schnur JB, Montgomery GH. A meta-analysis of the relationship between response expectancies and cancer treatment-related side effects. J Pain Symptom Manage. 2009;38:775–784. doi: 10.1016/j.jpainsymman.2009.01.008.
    1. Nestoriuc Y, Schuricht F, von Blanckenburg P, Albert US, Rief W. Der Einfluss von Erwartungen auf den Behandlungsverlauf der Antihormonellen Therapie bei Brustkrebs-Patientinnen [abstract] Verhaltenstherapie. 2011;21(Suppl 1):17.
    1. Nestoriuc Y, Schuricht F, von Blanckenburg P, Rief W, Albert US. Communicating side effects by informing about possible benefits and harms: effects on breast cancer patients’ satisfaction, knowledge and expectations [abstract] J Cancer Res Clin Oncol. 2012;138(Suppl 1):77.
    1. Rozema H, Völlink T, Lechner L. The role of illness representations in coping and health of patients treated for breast cancer. Psycho-Oncol. 2009;18:849–857. doi: 10.1002/pon.1488.
    1. Leventhal H, Nerenz D, Steele DJ. In: Handbook of psychology and health volume IV social psychology aspects of health. Baum A, Taylor SE, Singer JE, editor. Hillsdale, New Jersey: Erlbaum; 1984. Illness representations and coping with health threats; pp. 219–252.
    1. McGinty HL, Goldenberg JL, Jacobsen PB. Relationship of threat appraisal with coping appraisal to fear of cancer recurrence in breast cancer survivors. Psycho-Oncol. 2012;21:203–210. doi: 10.1002/pon.1883.
    1. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147:260–271. doi: 10.1016/j.neuroscience.2007.02.020.
    1. Liu L, Fiorentino L, Natarajan L, Parker BA, Mills PJ, Sadler GR, Dimsdale JE, Rissling M, He F, Ancoli-Israel S. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psycho-Oncol. 2009;18:187–194. doi: 10.1002/pon.1412.
    1. de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010;116:766–774. doi: 10.1002/cncr.24751.
    1. Fischer MJ, Wiesenhaan ME, Heijer AD-d, Kleijn WC, Nortier JWR, Kaptein AA. From despair to hope: a longitudinal study of illness perceptions and coping in a psycho-educational group intervention for women with breast cancer. Br J Health Psychol. 2012. DOI:10.1111/j.2044-8287.2012.02100.x.
    1. Roscoe JA, O’Neill M, Jean-Pierre P, Heckler CE, Kaptchuk TJ, Bushunow P, Shayne M, Huston A, Qazi R, Smith B. An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea. J Pain Symptom Manage. 2010;40:379–390. doi: 10.1016/j.jpainsymman.2009.12.024.
    1. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med. 2011;73:598–603. doi: 10.1097/PSY.0b013e3182294a50.
    1. Duijts SFA, van Beurden M, Oldenburg HSA, Hunter MS, Kieffer JM, Stuiver MM, Gerritsma MA, Menke-Pluymers MBE, Plaisier PW, Rijna H. et al.Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012;30:4124–4133. doi: 10.1200/JCO.2012.41.8525.
    1. Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, Hunter MS. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13:309–318. doi: 10.1016/S1470-2045(11)70364-3.
    1. Margraf J. Diagnostisches Kurz-Interview bei psychischen Störungen (Mini-DIPS) Göttingen: Hogrefe; 1994.
    1. Faul F, Erdfelder E, Lang A-G, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–191. doi: 10.3758/BF03193146.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Herrmann C, Buss U, Snaith RR. Hospital anxiety and depression scale - Deutsche Version (HADS-D): manual. Bern: Huber; 1995.
    1. Abramson J. WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov. 2011;8:1. doi: 10.1186/1742-5573-8-1.
    1. McGurk R, Fallowfield L, Winters Z. Information provision for patients by breast cancer teams about the side-effects of hormone treatments. Eur J Cancer. 2006;42:1760–1767. doi: 10.1016/j.ejca.2006.03.014.
    1. Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol. 2007;18:36–44.
    1. Hautzinger M. Die Plazebokontrollgruppe in der Psychotherapieforschung. Psychotherapie. 2001;6:199–204.
    1. Markowitz JC, Manber R, Rosen P. Therapists’ responses to training in brief supportive psychotherapy. Am J Psychother. 2008;62:67–81.
    1. Cohen L, Parker PA, Vence L, Savary C, Kentor D, Pettaway C, Babaian R, Pisters L, Miles B, Wei Q. et al.Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med. 2011;73:218–225. doi: 10.1097/PSY.0b013e31820a1c26.
    1. Rief W, Barsky AJ, Glombiewski JA, Nestoriuc Y, Glaesmer H, Braehler E. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011;20:405–415. doi: 10.1002/pds.2067.
    1. Rief W, Glombiewski JA, Barsky AJ. General assessment of side effects: GASE. Bern: Huber (electronic version); 2009.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Canc Inst. 1993;85:365–376. doi: 10.1093/jnci/85.5.365.
    1. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P. et al.The European organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756–2768.
    1. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1. doi: 10.1080/08870449908407311.
    1. Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, Jank S. Assessing reported adherence to pharmacological treatment recommendations. translation and evaluation of the medication adherence report scale (MARS) in Germany. J Eval Clin Pract. 2010;16:574–579.
    1. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97–102. doi: 10.1016/j.pec.2004.10.005.
    1. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631–637. doi: 10.1016/j.jpsychores.2005.10.020.
    1. Grunfeld EA, Low E, Cooper AF. Cancer survivors’ and employers’ perceptions of working following cancer treatment. Occup Med. 2010;60:611–617. doi: 10.1093/occmed/kqq143.
    1. Mehnert A, Herschbach P, Berg P, Henrich G, Koch U. Progredienzangst bei Brustkrebspatientinnen–Validierung der Kurzform des Progredienzangstfragebogens PA-F-KF. Z Psychosom Med Psychother. 2006;52:274–288.
    1. Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psycho-Oncol. 2009;18:1273–1280. doi: 10.1002/pon.1481.
    1. Alexander S, Palmer C, Stone P. Evaluation of screening instruments for depression and anxiety in breast cancer survivors. Breast Cancer Res Treat. 2010;122:573–578. doi: 10.1007/s10549-009-0669-6.
    1. Albert US, Zemlin C, Hadji P, Ziller V, Kuhler B, Frank-Hahn B, Wagner U, Kalder M. The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care. 2011;6(3):221–226. doi: 10.1159/000329006.
    1. Barsky AJ, Goodson JD, Lane RS, Cleary PD. The amplification of somatic symptoms. Psychosom Med. 1988;50:510–519.
    1. Gurevich M, Devins GM, Wilson C, McCready D, Marmar CR, Rodin GM. Stress response syndromes in women undergoing mammography: a comparison of women with and without a history of breast cancer. Psychosom Med. 2004;66:104–112. doi: 10.1097/01.PSY.0000109907.78754.5A.
    1. Kliem S, Job A-K, Kröger C, Bodenmann G, Stöbel-Richter Y, Hahlweg K, Brähler E. Entwicklung und Normierung einer Kurzform des Partnerschaftsfragebogens (PFB-K) an einer repräsentativen deutschen Stichprobe. Z Klin Psychol Psychother. 2012;41:81–89. doi: 10.1026/1616-3443/a000135.
    1. Terman LM, Butterwieser P, Ferguson LW, Johnson WB, Wilson DP. Psychological factors in marital happiness. New York: McGraw-Hill; 1983.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit